German pharmaceutical leader Bayer has reported encouraging Phase III results for asundexian, its next-generation anticoagulant. The update marks a significant comeback two years after a major clinical setback for the same drug.
A Strong Phase III Win
Bayer announced that a daily 50 mg dose of asundexian significantly reduced the risk of ischemic stroke compared with placebo.
These results come from the OCEANIC-STROKE study. Full data will be shared at an upcoming scientific congress. Bayer also plans to engage with regulatory authorities worldwide to prepare for marketing authorisation submissions.
Why This Matters?
Asundexian has long been positioned as one of Bayer’s most promising pipeline assets.
The company previously estimated peak sales of over €5 billion, potentially making it the most valuable drug in its portfolio.
A Comeback After a Major Setback
In late 2023, asundexian failed a pivotal clinical trial involving patients with atrial fibrillation who were at risk of stroke. That outcome raised doubts about the drug’s future.
The new findings from OCEANIC-STROKE restore momentum and suggest a possible path forward for the anticoagulant.
What’s Next
Bayer aims to:
- Present full Phase III results at a scientific congress
- Begin global discussions with regulators
- Prepare formal marketing authorisation applications
If approvals follow, asundexian could still become a major entrant in the global anticoagulant market.
